Epizyme, Inc.

James Edward John Mills

Kevin Wayne Kuntz

Michael John Munchhof

Lorna Helen Mitchell

Megan Alene Cloonan Foley

Darren Martin Harvey

Richard Chesworth

Kenneth William Duncan

John Emmerson Campbell

Andrew Simon Bell

Megan Alene Foley

The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Substituted piperidine compounds

The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Isoxazole carboxamide compounds

The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer

Growing community of inventors

Kent, United Kingdom

James Edward John Mills